Analyst Reiterates Buy on Palvella, Sees Market Overreaction to CVM Setback and Maintains $227 Price Target
Complete. Here is the key summaryCanaccord Genuity analyst Whitney Ijem reiterated a Buy rating on Palvella Therapeutics with a $227 price target, viewing the recent stock decline as an overreaction to a CVM setback. The analyst maintains that fundamentals remain strong, citing continued Fast Track status and progress in the mLM program. TD Cowen also reiterated a Buy rating with a $267 target.
Whitney Ijem, an analyst from Canaccord Genuity, reiterated the Buy rating on Palvella Therapeutics. The associated price target remains the same with $227.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Whitney Ijem has given his Buy rating due to a combination of factors tied to Palvella’s core programs and regulatory path. He views the sharp share decline following the CVM breakthrough therapy designation update as disconnected from fundamentals, since the company still holds Fast Track status, remains on schedule for a phase 3 CVM trial in 4Q26, and continues to pursue a viable single‑arm study design.
He also emphasizes that the setback in CVM does not affect the more advanced mLM program, where regulatory momentum is strong, including a completed pre‑NDA meeting, rolling review, and initial NDA module submission, all supporting a potential U.S. launch in 1H27. In his view, today’s market reaction creates an attractive entry point ahead of anticipated continued regulatory progress and commercial launch, justifying a reiterated Buy rating and an unchanged $227 price target.
In another report released today, TD Cowen also reiterated a Buy rating on the stock with a $267.00 price target.